全文获取类型
收费全文 | 32327篇 |
免费 | 3131篇 |
国内免费 | 126篇 |
专业分类
耳鼻咽喉 | 331篇 |
儿科学 | 1063篇 |
妇产科学 | 631篇 |
基础医学 | 4569篇 |
口腔科学 | 410篇 |
临床医学 | 3931篇 |
内科学 | 7028篇 |
皮肤病学 | 763篇 |
神经病学 | 3472篇 |
特种医学 | 1035篇 |
外国民族医学 | 1篇 |
外科学 | 4731篇 |
综合类 | 237篇 |
一般理论 | 30篇 |
预防医学 | 2766篇 |
眼科学 | 394篇 |
药学 | 1887篇 |
中国医学 | 65篇 |
肿瘤学 | 2240篇 |
出版年
2023年 | 107篇 |
2022年 | 100篇 |
2021年 | 576篇 |
2020年 | 489篇 |
2019年 | 881篇 |
2018年 | 1001篇 |
2017年 | 811篇 |
2016年 | 828篇 |
2015年 | 1019篇 |
2014年 | 1240篇 |
2013年 | 1721篇 |
2012年 | 2034篇 |
2011年 | 2234篇 |
2010年 | 1429篇 |
2009年 | 1314篇 |
2008年 | 1927篇 |
2007年 | 1999篇 |
2006年 | 1946篇 |
2005年 | 2007篇 |
2004年 | 1930篇 |
2003年 | 1944篇 |
2002年 | 2004篇 |
2001年 | 320篇 |
2000年 | 263篇 |
1999年 | 327篇 |
1998年 | 398篇 |
1997年 | 371篇 |
1996年 | 292篇 |
1995年 | 332篇 |
1994年 | 275篇 |
1993年 | 258篇 |
1992年 | 184篇 |
1991年 | 196篇 |
1990年 | 173篇 |
1989年 | 138篇 |
1988年 | 150篇 |
1987年 | 155篇 |
1986年 | 143篇 |
1985年 | 137篇 |
1984年 | 152篇 |
1983年 | 118篇 |
1982年 | 173篇 |
1981年 | 172篇 |
1980年 | 151篇 |
1979年 | 97篇 |
1978年 | 100篇 |
1977年 | 90篇 |
1976年 | 71篇 |
1975年 | 62篇 |
1972年 | 67篇 |
排序方式: 共有10000条查询结果,搜索用时 35 毫秒
1.
Barouyr Baroudjian Dimitri Arangalage Stefania Cuzzubbo Baptiste Hervier Celeste Lebbé Gwenael Lorillon 《Expert review of anticancer therapy》2019,19(3):209-222
Introduction: Immune checkpoint inhibitors (ICI) are now a standard of care in the treatment of many cancers leading to durable responses in patients with metastatic disease. These agents are generally well tolerated but may lead to the occurrence of immune-related adverse events (irAEs). As any organ may be affected, clinicians should be aware of the broad range of clinical manifestations and symptoms and keep in mind that toxicities may occur late, at any point along a patient’s treatment course. Although the most common irAEs are rarely severe, some of them may be associated with great morbidity and even become life-threatening. The rate of occurrence, type and severity of irAEs may vary with the type of ICI; thus, grade 3 and 4 irAEs are reported in more than 55% of patients treated with the combination of ipilimumab 3 mg/kg and nivolumab 1 mg/kg.
Area covered: This review presents the management of irAEs resulting from checkpoint blockade, with a focus on rare irAEs.
Expert commentary: With the development of immuno-oncology and the expanding role of ICI, physicians have learnt to diagnose and treat most of the irAEs that can occur. This review provides an overview of current guidelines, previously published studies and our multidisciplinary team based practices. 相似文献
2.
Evelyne Harkemanne Jean‐Louis Dargent Pierre‐Paul Roquet‐Gravy Audrey Bulinckx 《Pediatric dermatology》2019,36(3):365-367
We report a case of benign lymphoplasmacytic plaque (LPP) in a child. These asymptomatic erythematous papulonodular lesions are an emerging clinicopathological entity. Herein, we describe a previously unreported site for LPP lesions, namely, the volar wrist and the distal ipsilateral palm. 相似文献
3.
Jean‐Franois Etter 《Addiction (Abingdon, England)》2019,114(12):2252-2256
4.
5.
6.
7.
The National DMEFP Conference Team which consists of the following authors Charlene M. Dewey Teri L. Turner Linda Perkowski Jean Bailey Larry D. Gruppen 《Medical teacher》2016,38(2):141-149
Medical education fellowship programs (MEFPs) are a form of faculty development contributing to an organization’s educational mission and participants’ career development. Building an MEFP requires a systematic design, implementation, and evaluation approach which aligns institutional and individual faculty goals. Implementing an MEFP requires a team of committed individuals who provide expertise, guidance, and mentoring. Qualified MEFP directors should utilize instructional methods that promote individual and institutional short and long term growth. Directors must balance the use of traditional design, implementation, and evaluation methodologies with advancing trends that may support or threaten the acceptability and sustainability of the program. Drawing on the expertise of 28 MEFP directors, we provide twelve tips as a guide to those implementing, sustaining, and/or growing a successful MEFP whose value is demonstrated by its impacts on participants, learners, patients, teaching faculty, institutions, the greater medical education community, and the population’s health. 相似文献
8.
9.
PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease 下载免费PDF全文
10.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献